Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track KROS with free AI briefings, catalyst countdowns, and dilution alerts.

KROS · Keros Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$259.5M Cash on Hand
91.4mo Cash Runway
Follow KROS by email Get an email when KROS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about KROS, unsubscribe in one click. Privacy

📣 What KROS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Dose A KER-012 Pulmonary Arterial Hypertension Phase 2 · NCT05975905 Terminated
Dose B KER-012 Pulmonary Arterial Hypertension Phase 2 · NCT05975905 Terminated
Dose C KER-012 Pulmonary Arterial Hypertension Phase 2 · NCT05975905 Terminated
KER-047 Iron Deficiency Anemia Phase 2 · NCT05927012 Withdrawn
Rinvatercept Duchenne Muscular Dystrophy Phase 2 · NCT07704099 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

KROS holds $259.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $8.5M/quarter from operations, an estimated runway of 91.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 15 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KROS files for a raise →

👥 Who Owns KROS

Insiders 4.2% Institutions (192 holders) 95.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
BlackRock Portfolio Management LLC Institution (13G, 5%+) 1,813,870 9.24% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 1,671,343 8.52% 2026-06-30
Nantahala Capital Management, LLC Institution (13G, 5%+) 1,360,419 6.93% 2026-03-31
Jasbir Seehra
CHIEF EXECUTIVE OFFICER, Director · +576,944 options
Insider 440,708 2.25% 2026-04-02
Julius Knowles
Director · +7,433 options
Insider 113,191 0.58% 2026-06-04
Annita Tanini
Corp. Controller & VP, Finance
Insider 45,144 0.23% 2026-08-18
ORBIMED ADVISORS LLC
Director
Insider 45,057 0.23% 2025-11-21
Carl L Gordon
Director
Includes shares also reported by ORBIMED ADVISORS LLC, counted once
Insider 45,057 0.23% 2025-11-21
Keith Regnante
CHIEF FINANCIAL OFFICER · +60,000 options
Insider 39,261 0.20% 2026-02-18
Esther Cho
Chief Legal Officer · +80,000 options
Insider 35,770 0.18% 2026-08-18
Lorena Raquel Lerner
Chief Scientific Officer · +75,000 options
Insider 27,559 0.14% 2026-08-18
Jean Jacques Bienaime
Director · +7,433 options
Insider 19,592 0.10% 2026-08-17

Share count 19,624,374 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full KROS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KROS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.